Systemic and mucosal immune responses in mice orally immunized with avirulent Salmonella typhimurium expressing a cloned Porphyromonas gingivalis hemagglutinin

Abstract

Porphyromonas gingivalis produces a variety of virulence factors that may have a function in the periodontal disease process. Determination of the role of these various factors in pathogenesis and identification of a means for protecting the host from the destructive effects of this organism are areas of vigorous investigation. In this study we demonstrate the potential of avirulent Salmonella typhimurium strains to stimulate a specific systemic and mucosal immune response to a cloned P. gingivalis hemagglutinin (HagB). An avirulent strain of S. typhimurium, X4072, expressing the hagB gene ofP. gingivalis 381 on the plasmid pDMD1 was intragastrically

Humoral immune response to Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in periodontal disease

“…gingivalis has been cloned into an avirulent strains of S. typhimurium (77). This strain was subsequently used to orally immunize mice and elicited a systemic and mucosal response to this antigen (75,76). It remains to be determined what the capacity of this vaccination is to induce protection from I!…”

A recombinant Salmonella typhimurium vaccine induces local immunity by four different routes of immunization

“…To date, only the oral and rectal routes of administration have been investigated with Salmonella vaccines. Both routes of immunization induced a systemic and mucosal response characterized by the presence of sIgA in saliva and in intestinal secretions (7,8). Although it has been proposed that such vaccines could also induce specific sIgA in the genital tract, so far this has not been tested (6,23).…”

Mucosal Vaccination Shapes the Expression of Salivary Antibodies and Establishment of CD8+ T‐Cells

“…Dusek at el. 11 found that the mucosal vaccination led to faster and more significant serum IgG response than the saliva IgA response. The difference between these results may stem from the way the vaccination was administered by Dusek et al, i.e., gastric intubation, which may cause local injury to the gastrointestinal tract and lead to a systemic response (similar to subcutaneous vaccination).…”

“…Dusek at el. 11 demonstrated the feasibility of inducing a systemic and mucosal immune response, using an oral mucosal vaccination containing P. gingivalis hemagglutinin. It was shown that antibodies expression (immunoglobulin A [IgA] and IgG) increased with time, peaking at 5 weeks after vaccination.…”

“…It was shown that antibodies expression (immunoglobulin A [IgA] and IgG) increased with time, peaking at 5 weeks after vaccination. 11 Zhang et al 12 showed that nasal vaccination with P. gingivalis Kgp (lysine gingipain) protease resulted in a high specific antibody level in both serum and saliva, as well as the establishment of memory lymphocytes in the neighboring lymph nodes. Moreover, it was shown that the vaccination was more potent when an adjuvant (cholera toxin [CT]) was added.…”